[1] |
LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin.
Ethical analysis and countermeasures of artificial intelligence application in clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
|
[2] |
WANG Yaya, CHU Zixuan, YANG Junling, Olajide E. Olaleye, HE Rongrong, LI Muzi, CHENG Chen, LI Chuan.
Potential health benefits of resveratrol: a pharmacokinetics-caused conundrum
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(8): 931-954.
|
[3] |
GAO Lili, CHEN Rui, LI Lujin, ZHENG Qingshan .
Dose selection of obeticholic acid in hepatic impairment patients and the review consideration of FDA
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 760-767.
|
[4] |
OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin.
Ethical issues and countermeasures of early phase trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
|
[5] |
XIE Mengsheng, ZHAO Yang, CHEN Feng.
Statistical analysis of active extension trial
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1007-1013.
|
[6] |
ZHANG Yanping, PEI Tong, HU Chaoying, ZHANG Lan.
Brief analysis on the measures for the management of instruments and equipment in phase Ⅰ drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 890-894.
|
[7] |
LI Jian, YAN Fang, YANG Jinbo, WANG Yuzhu.
Application of model-informed drug development approach in dose optimization: Insights from the modification of nivolumab dosage regimen
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(4): 408-412.
|
[8] |
QIN Qun, LIU Xiaobao, YANG Guoping, LI Zhuo, LI Kunyan, HUANG Zhijun, LIU Zhaoqian.
COVID-19:Emergency response measures for GCP in Hunan province under the first level response of major public health emergencies(2.0 Version)
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 323-328.
|
[9] |
.
Research progress of linezolid-induced lactic acidosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1408-1413.
|
[10] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Applications of model-informed drug development (MIDD) on new drug research and development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
|
[11] |
MA Guangli, XU Ling, CHEN Rui, CHEN Yuancheng, ZHAO Wei, LIU Dongyang, JIAO Zheng, LI Jian, JI Shuangmin, LI Li, LI Liang, WANG Yuzhu, YANG Jinbo, WANG Yaning, SUN He, HU Pei, ZHENG Qingshan, LU Wei.
General considerations of population pharmacokinetic/pharmacodynamic study in new drug development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1201-1220.
|
[12] |
LI Xiao, LIU Yang, WANG Xinyi.
Problems and countermeasures in the supervision of clinical trials of medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 841-845.
|
[13] |
ZHANG Yongxue, HE Qing, ZHANG Xiaoyu, ZHANG Wenxin, ZHAO Qingzhong, WANG Zhiwei, GAO Shan.
GC-MS-based a carrier gas purge experimental device to test the electronic smoke nicotine concentration
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 776-781.
|
[14] |
PENG Peng, YUAN Wei'an, HU Yihui, TANG Jie, JIANG Jian.
Analysis of regulatory issues of adverse events in drug clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 78-82.
|
[15] |
LIU Shijia, CHEN Du, YIN Jungang, CHU Jihong, XU Meijuan, LIU Fang, DAI Guoliang, XIONG Ningning, JU Wenzheng.
Comparison of the pharmacokinetics of levetiracetam injection and levetiracetam tablets in human
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 294-298.
|